Display options
Cite
VanCleave A, Palmer M, Fang F, et al. Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway. Oncotarget. 2020;11(27):2597-2610doi: 10.18632/oncotarget.27611.
VanCleave, A., Palmer, M., Fang, F., Torres, H., Rodezno, T., Li, Q., Fuglsby, K., Evans, C., Afeworki, Y., Ross, A., Rao, P., Leiferman, P., Zheng, S., Houghton, P., & Tao, J. (2020). Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway. Oncotarget, 11(27), 2597-2610. https://doi.org/10.18632/oncotarget.27611
VanCleave, Ashley, et al. "Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway." Oncotarget vol. 11,27 (2020): 2597-2610. doi: https://doi.org/10.18632/oncotarget.27611
VanCleave A, Palmer M, Fang F, Torres H, Rodezno T, Li Q, Fuglsby K, Evans C, Afeworki Y, Ross A, Rao P, Leiferman P, Zheng S, Houghton P, Tao J. Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway. Oncotarget. 2020 Jul 07;11(27):2597-2610. doi: 10.18632/oncotarget.27611. eCollection 2020 Jul 07. PMID: 32676162; PMCID: PMC7343631.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2020 Jul 07;11(27):2597-2610. doi: 10.18632/oncotarget.27611. eCollection 2020 Jul 07.

Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway.

Oncotarget

Ashley VanCleave, Mykayla Palmer, Fang Fang, Haydee Torres, Tania Rodezno, Qilin Li, Kirby Fuglsby, Claire Evans, Yohannes Afeworki, Alan Ross, Pulivarthi Rao, Patricia Leiferman, Siyuan Zheng, Peter Houghton, Jianning Tao

Affiliations

  1. Cancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD, USA.
  2. SPUR Scholar Program, University of South Dakota, Sioux Falls, SD, USA.
  3. Department of Chemistry and Biochemistry, South Dakota State University, Brookings, SD, USA.
  4. Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
  5. Department of Biomedical Engineering, University of South Dakota, Sioux Falls, SD, USA.
  6. Functional Genomics & Bioinformatics Core Facility, Sanford Research, Sioux Falls, SD, USA.
  7. Sanford Medical Genetics Laboratory of Sanford Health, Sioux Falls, SD, USA.
  8. Texas Children's Cancer and Hematology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
  9. EGL Genetics Laboratory, Tucker, GA, USA.
  10. Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA.

PMID: 32676162 PMCID: PMC7343631 DOI: 10.18632/oncotarget.27611

Abstract

Outcomes have not improved for metastatic osteosarcoma for several decades. In part, this failure to develop better therapies stems from a lack of understanding of osteosarcoma biology, given the rarity of the disease and the high genetic heterogeneity at the time of diagnosis. We report here the successful establishment of a new human osteosarcoma cell line, COS-33, from a patient-derived xenograft and demonstrate retention of the biological features of the original tumor. We found high mTOR signaling activity in the cultured cells, which were sensitive to a small molecule inhibitor, rapamycin, a suppressor of the mTOR pathway. Suppressed mTOR signaling after treatment with rapamycin was confirmed by decreased phosphorylation of the S6 ribosomal protein. Increasing concentrations of rapamycin progressively inhibited cell proliferation

Keywords: COS-33; TP53; mTOR; osteogenic differentiation; osteosarcoma

Conflict of interest statement

CONFLICTS OF INTEREST The authors have no conflicts of interest to report.

References

  1. Invest New Drugs. 2012 Jun;30(3):916-26 - PubMed
  2. Methods Mol Biol. 2005;294:15-22 - PubMed
  3. Lab Invest. 2011 Aug;91(8):1195-205 - PubMed
  4. Int J Cancer. 1967 Sep 15;2(5):434-47 - PubMed
  5. Cancer Res. 1989 Oct 1;49(19):5407-13 - PubMed
  6. Appl Mater Today. 2018 Mar;10:194-202 - PubMed
  7. Int J Cancer. 2014 Dec 15;135(12):2770-82 - PubMed
  8. Genes Chromosomes Cancer. 2010 Jan;49(1):40-51 - PubMed
  9. Nature. 2010 Aug 26;466(7310):1110-4 - PubMed
  10. Br J Cancer. 2013 Oct 15;109(8):2228-36 - PubMed
  11. Int J Cancer. 2009 Jul 1;125(1):229-34 - PubMed
  12. Genes Dev. 2008 Jun 15;22(12):1662-76 - PubMed
  13. Cell Rep. 2014 Apr 10;7(1):104-12 - PubMed
  14. BMC Med Genomics. 2011 Sep 20;4:66 - PubMed
  15. PLoS One. 2012;7(11):e48262 - PubMed
  16. ACS Appl Mater Interfaces. 2016 Nov 30;8(47):32450-32459 - PubMed
  17. Cell. 2011 Nov 23;147(5):992-1009 - PubMed
  18. Cancer. 2019 Oct 15;125(20):3514-3525 - PubMed
  19. Pediatr Blood Cancer. 2010 Jul 15;55(1):67-75 - PubMed
  20. Nat Protoc. 2007;2(2):329-33 - PubMed
  21. Cell Rep. 2019 Nov 5;29(6):1675-1689.e9 - PubMed
  22. Genome Res. 2009 Sep;19(9):1639-45 - PubMed
  23. Oncotarget. 2016 Dec 27;7(52):86594-86607 - PubMed
  24. Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5564-73 - PubMed
  25. Pediatr Blood Cancer. 2008 Apr;50(4):799-805 - PubMed
  26. Nat Genet. 2015 Jun;47(6):615-24 - PubMed
  27. Genome Res. 2016 Jan;26(1):119-29 - PubMed
  28. Oncogene. 2015 Aug 6;34(32):4278-84 - PubMed
  29. Cancer Cell. 2014 Sep 8;26(3):390-401 - PubMed
  30. Cancer Res. 1990 May 1;50(9):2781-5 - PubMed
  31. Bone. 2017 Sep;102:69-79 - PubMed
  32. Pediatr Blood Cancer. 2007 Dec;49(7):928-40 - PubMed
  33. J Natl Cancer Inst. 2019 Nov 1;111(11):1216-1227 - PubMed
  34. Cancer Discov. 2019 Jan;9(1):46-63 - PubMed
  35. Cancer Chemother Pharmacol. 1992;31(3):229-39 - PubMed
  36. Antimicrob Agents Chemother. 1977 Jul;12(1):11-5 - PubMed
  37. Oncotarget. 2018 Dec 4;9(95):36780-36792 - PubMed
  38. J Cell Biol. 2006 Mar 13;172(6):909-21 - PubMed
  39. Cancer Chemother Pharmacol. 2009 Sep;64(4):733-40 - PubMed
  40. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11547-52 - PubMed

Publication Types

Grant support